Haemonetics reported third-quarter fiscal 2026 earnings per share of $1.31, surpassing the consensus estimate of $1.27 and improving from $1.19 in the year-ago period. The company generated organic revenue growth of 6.5% on a constant-currency basis, excluding the impact of foreign exchange, the divestiture of its whole blood product line and the exit from certain liquid solution products. Reported revenue for the quarter was $360 million, up 4% year-over-year, driven by strength in the Surgical and Transfusion franchises. Operating income margin expanded by 120 basis points to 18.3%, reflecting ongoing cost efficiencies and supply chain optimization initiatives.